FIELD: pharmaceutics.
SUBSTANCE: invention refers to antiviral agents and concerns an anti-COVID-19 (SARS-CoV-2) viral pharmaceutical composition containing favipiravir which is presented in the form of film-coated tablets. Disclosed composition comprises: 43–44 % of micronised favipiravir with particle size of 40–50 mcm, 5.5–6.0 % sodium croscarmellose, 4.8–5.0 % povidone, 0.6–0.8 % magnesium stearate, 0.5–0.7 % of colloidal silica, 2.5–2.7 % of film shell and microcrystalline cellulose – the rest.
EFFECT: said composition provides fast release of favipiravir from a dosage form (tablets).
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
| COVID-19 (SARS-COV-2) COMBINATION THERAPY AND TREATMENT METHOD | 2020 |
|
RU2745986C1 |
| PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION | 2020 |
|
RU2746161C1 |
| ANTI-CORONAVIRUS AGENT FOR COVID-19 COMBINATION THERAPY (SARS-COV-2) | 2020 |
|
RU2742116C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID, DRUG CONTAINING IT, AS WELL AS THEIR USE FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2022 |
|
RU2814927C1 |
